Thursday, May 15, 2014

Seeking Alpha: LipoScience Nearly Back To Square One

LipoScience (LPDX) has developed a blood test (NMR LipoProfile) that has the potential to meaningfully improve outcomes for patients at risk of cholesterol-related cardiovascular problems, but it takes more than an FDA-approved test to make a business work. LipoScience is perilously close to becoming a company with a great future in its past, as the company continues to struggle to generate commercial interest in its test. A journal article based upon a retrospective analysis of LDL-P measurement could help spur interest and a takeover is a credible potential outcome, but LipoScience's current circumstances make this a highly speculative stock.

Please read more here:
LipoScience Nearly Back To Square One

No comments: